Avidity Biosciences Inc (NASDAQ: RNAM) Stock Competitors & Peer Comparison
See RNAM's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for RNAM and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| RNAM | $72.86 | +0.05% | 11.3B | -17.39 | -$4.19 | N/A |
| VRTX | $490.39 | +2.38% | 124.4B | 26.05 | $18.82 | N/A |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| REGN | $695.18 | +4.20% | 71.6B | 15.24 | $45.63 | +0.54% |
| ARGX | $872.23 | -1.87% | 54.2B | 78.72 | $11.08 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| RVMD | $183.86 | -2.24% | 39.1B | -26.01 | -$7.07 | N/A |
| ALNY | $288.41 | +3.60% | 38.5B | 51.97 | $5.55 | N/A |
| RVMDW | $9.01 | -5.65% | 37.4B | -2.13 | -$4.15 | N/A |
| ONC | $330.46 | +1.40% | 35.3B | 73.93 | $4.47 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
RNAM vs VRTX Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, VRTX has a market cap of 124.4B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while VRTX trades at $490.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas VRTX's P/E ratio is 26.05. In terms of profitability, RNAM's ROE is -0.45%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, RNAM is less volatile compared to VRTX. This indicates lower risk in terms of short-term price fluctuations for RNAM.Check VRTX's competition here
Verona Pharma plc (NASDAQ: VRNA)
RNAM vs VRNA Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas VRNA's P/E ratio is -102.80. In terms of profitability, RNAM's ROE is -0.45%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, RNAM is similarly volatile compared to VRNA. This indicates similar risk in terms of short-term price fluctuations for RNAM.Check VRNA's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
RNAM vs REGN Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, REGN has a market cap of 71.6B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while REGN trades at $695.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas REGN's P/E ratio is 15.24. In terms of profitability, RNAM's ROE is -0.45%, compared to REGN's ROE of +0.14%. Regarding short-term risk, RNAM is less volatile compared to REGN. This indicates lower risk in terms of short-term price fluctuations for RNAM.Check REGN's competition here
argenx SE (NASDAQ: ARGX)
RNAM vs ARGX Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, ARGX has a market cap of 54.2B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while ARGX trades at $872.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas ARGX's P/E ratio is 78.72. In terms of profitability, RNAM's ROE is -0.45%, compared to ARGX's ROE of +0.32%. Regarding short-term risk, RNAM is less volatile compared to ARGX. This indicates lower risk in terms of short-term price fluctuations for RNAM.Check ARGX's competition here
Seagen Inc. (NASDAQ: SGEN)
RNAM vs SGEN Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas SGEN's P/E ratio is -57.19. In terms of profitability, RNAM's ROE is -0.45%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, RNAM is less volatile compared to SGEN. This indicates lower risk in terms of short-term price fluctuations for RNAM.Check SGEN's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
RNAM vs RVMD Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, RVMD has a market cap of 39.1B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while RVMD trades at $183.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas RVMD's P/E ratio is -26.01. In terms of profitability, RNAM's ROE is -0.45%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, RNAM is less volatile compared to RVMD. This indicates lower risk in terms of short-term price fluctuations for RNAM.Check RVMD's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
RNAM vs ALNY Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, ALNY has a market cap of 38.5B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while ALNY trades at $288.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas ALNY's P/E ratio is 51.97. In terms of profitability, RNAM's ROE is -0.45%, compared to ALNY's ROE of +0.98%. Regarding short-term risk, RNAM is less volatile compared to ALNY. This indicates lower risk in terms of short-term price fluctuations for RNAM.Check ALNY's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
RNAM vs RVMDW Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, RVMDW has a market cap of 37.4B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while RVMDW trades at $9.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas RVMDW's P/E ratio is -2.13. In terms of profitability, RNAM's ROE is -0.45%, compared to RVMDW's ROE of -0.83%. Regarding short-term risk, RNAM is less volatile compared to RVMDW. This indicates lower risk in terms of short-term price fluctuations for RNAM.Check RVMDW's competition here
BeOne Medicines AG (NASDAQ: ONC)
RNAM vs ONC Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, ONC has a market cap of 35.3B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while ONC trades at $330.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas ONC's P/E ratio is 73.93. In terms of profitability, RNAM's ROE is -0.45%, compared to ONC's ROE of +0.12%. Regarding short-term risk, RNAM is less volatile compared to ONC. This indicates lower risk in terms of short-term price fluctuations for RNAM.Check ONC's competition here
Incyte Corporation (NASDAQ: INCY)
RNAM vs INCY Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, INCY has a market cap of 26B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while INCY trades at $129.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas INCY's P/E ratio is 17.46. In terms of profitability, RNAM's ROE is -0.45%, compared to INCY's ROE of +0.29%. Regarding short-term risk, RNAM is less volatile compared to INCY. This indicates lower risk in terms of short-term price fluctuations for RNAM.Check INCY's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
RNAM vs ROIV Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, ROIV has a market cap of 24.3B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while ROIV trades at $33.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas ROIV's P/E ratio is -34.78. In terms of profitability, RNAM's ROE is -0.45%, compared to ROIV's ROE of -0.07%. Regarding short-term risk, RNAM is less volatile compared to ROIV. This indicates lower risk in terms of short-term price fluctuations for RNAM.Check ROIV's competition here
BioNTech SE (NASDAQ: BNTX)
RNAM vs BNTX Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, BNTX has a market cap of 23.4B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while BNTX trades at $92.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas BNTX's P/E ratio is -20.01. In terms of profitability, RNAM's ROE is -0.45%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, RNAM is less volatile compared to BNTX. This indicates lower risk in terms of short-term price fluctuations for RNAM.Check BNTX's competition here
Insmed Incorporated (NASDAQ: INSM)
RNAM vs INSM Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, INSM has a market cap of 22.6B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while INSM trades at $104.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas INSM's P/E ratio is -18.11. In terms of profitability, RNAM's ROE is -0.45%, compared to INSM's ROE of -1.30%. Regarding short-term risk, RNAM is less volatile compared to INSM. This indicates lower risk in terms of short-term price fluctuations for RNAM.Check INSM's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
RNAM vs UTHR Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, UTHR has a market cap of 22.2B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while UTHR trades at $523.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas UTHR's P/E ratio is 19.32. In terms of profitability, RNAM's ROE is -0.45%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, RNAM is less volatile compared to UTHR. This indicates lower risk in terms of short-term price fluctuations for RNAM.Check UTHR's competition here
Moderna, Inc. (NASDAQ: MRNA)
RNAM vs MRNA Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, MRNA has a market cap of 22.1B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while MRNA trades at $55.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas MRNA's P/E ratio is -6.85. In terms of profitability, RNAM's ROE is -0.45%, compared to MRNA's ROE of -0.37%. Regarding short-term risk, RNAM is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for RNAM.Check MRNA's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
RNAM vs BGNE Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas BGNE's P/E ratio is -22.55. In terms of profitability, RNAM's ROE is -0.45%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, RNAM is less volatile compared to BGNE. This indicates lower risk in terms of short-term price fluctuations for RNAM.Check BGNE's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
RNAM vs DNA-WT Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, RNAM's ROE is -0.45%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, RNAM is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for RNAM.Check DNA-WT's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
RNAM vs NBIX Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, NBIX has a market cap of 18.4B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while NBIX trades at $182.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas NBIX's P/E ratio is 26.42. In terms of profitability, RNAM's ROE is -0.45%, compared to NBIX's ROE of +0.22%. Regarding short-term risk, RNAM is less volatile compared to NBIX. This indicates lower risk in terms of short-term price fluctuations for RNAM.Check NBIX's competition here
Genmab A/S (NASDAQ: GMAB)
RNAM vs GMAB Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, GMAB has a market cap of 17.8B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while GMAB trades at $29.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas GMAB's P/E ratio is 20.86. In terms of profitability, RNAM's ROE is -0.45%, compared to GMAB's ROE of +0.15%. Regarding short-term risk, RNAM is less volatile compared to GMAB. This indicates lower risk in terms of short-term price fluctuations for RNAM.Check GMAB's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
RNAM vs BBIO Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, BBIO has a market cap of 16.8B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while BBIO trades at $85.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas BBIO's P/E ratio is -22.87. In terms of profitability, RNAM's ROE is -0.45%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, RNAM is less volatile compared to BBIO. This indicates lower risk in terms of short-term price fluctuations for RNAM.Check BBIO's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
RNAM vs JAZZ Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, JAZZ has a market cap of 16.1B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while JAZZ trades at $256.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas JAZZ's P/E ratio is 19.98. In terms of profitability, RNAM's ROE is -0.45%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, RNAM is less volatile compared to JAZZ. This indicates lower risk in terms of short-term price fluctuations for RNAM.Check JAZZ's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
RNAM vs ASND Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, ASND has a market cap of 15.8B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while ASND trades at $254.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas ASND's P/E ratio is -105.14. In terms of profitability, RNAM's ROE is -0.45%, compared to ASND's ROE of -56.42%. Regarding short-term risk, RNAM is less volatile compared to ASND. This indicates lower risk in terms of short-term price fluctuations for RNAM.Check ASND's competition here
Exelixis, Inc. (NASDAQ: EXEL)
RNAM vs EXEL Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, EXEL has a market cap of 14.2B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while EXEL trades at $56.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas EXEL's P/E ratio is 16.92. In terms of profitability, RNAM's ROE is -0.45%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, RNAM is less volatile compared to EXEL. This indicates lower risk in terms of short-term price fluctuations for RNAM.Check EXEL's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
RNAM vs KRTX Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas KRTX's P/E ratio is -28.09. In terms of profitability, RNAM's ROE is -0.45%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, RNAM is less volatile compared to KRTX. This indicates lower risk in terms of short-term price fluctuations for RNAM.Check KRTX's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
RNAM vs MDGL Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, MDGL has a market cap of 12.4B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while MDGL trades at $538.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas MDGL's P/E ratio is -42.09. In terms of profitability, RNAM's ROE is -0.45%, compared to MDGL's ROE of -0.50%. Regarding short-term risk, RNAM is less volatile compared to MDGL. This indicates lower risk in terms of short-term price fluctuations for RNAM.Check MDGL's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
RNAM vs ARWR Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, ARWR has a market cap of 12.1B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while ARWR trades at $85.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas ARWR's P/E ratio is -39.90. In terms of profitability, RNAM's ROE is -0.45%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, RNAM is less volatile compared to ARWR. This indicates lower risk in terms of short-term price fluctuations for RNAM.Check ARWR's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
RNAM vs AXSM Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, AXSM has a market cap of 12.1B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while AXSM trades at $234.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas AXSM's P/E ratio is -61.15. In terms of profitability, RNAM's ROE is -0.45%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, RNAM is less volatile compared to AXSM. This indicates lower risk in terms of short-term price fluctuations for RNAM.Check AXSM's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
RNAM vs BMRN Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, BMRN has a market cap of 12B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while BMRN trades at $62.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas BMRN's P/E ratio is 29.84. In terms of profitability, RNAM's ROE is -0.45%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, RNAM is less volatile compared to BMRN. This indicates lower risk in terms of short-term price fluctuations for RNAM.Check BMRN's competition here
Bio-Techne Corporation (NASDAQ: TECH)
RNAM vs TECH Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, TECH has a market cap of 11.3B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while TECH trades at $72.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas TECH's P/E ratio is 37.15. In terms of profitability, RNAM's ROE is -0.45%, compared to TECH's ROE of +0.05%. Regarding short-term risk, RNAM is less volatile compared to TECH. This indicates lower risk in terms of short-term price fluctuations for RNAM.Check TECH's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
RNAM vs KRYS Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, KRYS has a market cap of 10.7B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while KRYS trades at $364.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas KRYS's P/E ratio is 48.69. In terms of profitability, RNAM's ROE is -0.45%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, RNAM is less volatile compared to KRYS. This indicates lower risk in terms of short-term price fluctuations for RNAM.Check KRYS's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
RNAM vs HALO Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, HALO has a market cap of 9.9B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while HALO trades at $83.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas HALO's P/E ratio is 18.06. In terms of profitability, RNAM's ROE is -0.45%, compared to HALO's ROE of +1.26%. Regarding short-term risk, RNAM is less volatile compared to HALO. This indicates lower risk in terms of short-term price fluctuations for RNAM.Check HALO's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
RNAM vs CYTK Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, CYTK has a market cap of 9.9B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while CYTK trades at $79.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas CYTK's P/E ratio is -13.63. In terms of profitability, RNAM's ROE is -0.45%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, RNAM is less volatile compared to CYTK. This indicates lower risk in terms of short-term price fluctuations for RNAM.Check CYTK's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
RNAM vs SMMT Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, SMMT has a market cap of 9.7B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while SMMT trades at $12.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas SMMT's P/E ratio is -7.84. In terms of profitability, RNAM's ROE is -0.45%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, RNAM is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for RNAM.Check SMMT's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
RNAM vs RXDX Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas RXDX's P/E ratio is -56.47. In terms of profitability, RNAM's ROE is -0.45%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, RNAM is less volatile compared to RXDX. This indicates lower risk in terms of short-term price fluctuations for RNAM.Check RXDX's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
RNAM vs IONS Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, IONS has a market cap of 9.1B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while IONS trades at $55.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas IONS's P/E ratio is -32.15. In terms of profitability, RNAM's ROE is -0.45%, compared to IONS's ROE of -0.59%. Regarding short-term risk, RNAM is less volatile compared to IONS. This indicates lower risk in terms of short-term price fluctuations for RNAM.Check IONS's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
RNAM vs NUVL Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas NUVL's P/E ratio is -21.79. In terms of profitability, RNAM's ROE is -0.45%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, RNAM is similarly volatile compared to NUVL. This indicates similar risk in terms of short-term price fluctuations for RNAM.Check NUVL's competition here
Abivax S.A. (NASDAQ: ABVX)
RNAM vs ABVX Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, ABVX has a market cap of 9.1B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while ABVX trades at $124.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas ABVX's P/E ratio is -65.12. In terms of profitability, RNAM's ROE is -0.45%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, RNAM is less volatile compared to ABVX. This indicates lower risk in terms of short-term price fluctuations for RNAM.Check ABVX's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
RNAM vs CRNX Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, CRNX has a market cap of 8.9B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while CRNX trades at $83.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas CRNX's P/E ratio is -16.35. In terms of profitability, RNAM's ROE is -0.45%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, RNAM is less volatile compared to CRNX. This indicates lower risk in terms of short-term price fluctuations for RNAM.Check CRNX's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
RNAM vs PTGX Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, PTGX has a market cap of 8.8B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while PTGX trades at $136.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas PTGX's P/E ratio is -75.60. In terms of profitability, RNAM's ROE is -0.45%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, RNAM is less volatile compared to PTGX. This indicates lower risk in terms of short-term price fluctuations for RNAM.Check PTGX's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
RNAM vs KYMR Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, KYMR has a market cap of 8.7B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while KYMR trades at $106.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas KYMR's P/E ratio is -30.07. In terms of profitability, RNAM's ROE is -0.45%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, RNAM is less volatile compared to KYMR. This indicates lower risk in terms of short-term price fluctuations for RNAM.Check KYMR's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
RNAM vs IMGN Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas IMGN's P/E ratio is -111.55. In terms of profitability, RNAM's ROE is -0.45%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, RNAM is less volatile compared to IMGN. This indicates lower risk in terms of short-term price fluctuations for RNAM.Check IMGN's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
RNAM vs SYRE Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, SYRE has a market cap of 8.7B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while SYRE trades at $99.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas SYRE's P/E ratio is -48.06. In terms of profitability, RNAM's ROE is -0.45%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, RNAM is less volatile compared to SYRE. This indicates lower risk in terms of short-term price fluctuations for RNAM.Check SYRE's competition here
Alkermes plc (NASDAQ: ALKS)
RNAM vs ALKS Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, ALKS has a market cap of 8.4B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while ALKS trades at $50.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas ALKS's P/E ratio is 53.16. In terms of profitability, RNAM's ROE is -0.45%, compared to ALKS's ROE of +0.09%. Regarding short-term risk, RNAM is less volatile compared to ALKS. This indicates lower risk in terms of short-term price fluctuations for RNAM.Check ALKS's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
RNAM vs TGTX Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, TGTX has a market cap of 8.4B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while TGTX trades at $54.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas TGTX's P/E ratio is 18.86. In terms of profitability, RNAM's ROE is -0.45%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, RNAM is less volatile compared to TGTX. This indicates lower risk in terms of short-term price fluctuations for RNAM.Check TGTX's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
RNAM vs BPMC Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas BPMC's P/E ratio is -51.58. In terms of profitability, RNAM's ROE is -0.45%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, RNAM is similarly volatile compared to BPMC. This indicates similar risk in terms of short-term price fluctuations for RNAM.Check BPMC's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
RNAM vs APGE Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, APGE has a market cap of 8.3B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while APGE trades at $134.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas APGE's P/E ratio is -30.99. In terms of profitability, RNAM's ROE is -0.45%, compared to APGE's ROE of -0.33%. Regarding short-term risk, RNAM is less volatile compared to APGE. This indicates lower risk in terms of short-term price fluctuations for RNAM.Check APGE's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
RNAM vs PRAX Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, PRAX has a market cap of 8.2B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while PRAX trades at $295.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas PRAX's P/E ratio is -22.12. In terms of profitability, RNAM's ROE is -0.45%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, RNAM is less volatile compared to PRAX. This indicates lower risk in terms of short-term price fluctuations for RNAM.Check PRAX's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
RNAM vs CERE Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas CERE's P/E ratio is -16.47. In terms of profitability, RNAM's ROE is -0.45%, compared to CERE's ROE of -0.72%. Regarding short-term risk, RNAM is less volatile compared to CERE. This indicates lower risk in terms of short-term price fluctuations for RNAM.Check CERE's competition here
Immunovant, Inc. (NASDAQ: IMVT)
RNAM vs IMVT Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, IMVT has a market cap of 8B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while IMVT trades at $38.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas IMVT's P/E ratio is -14.57. In terms of profitability, RNAM's ROE is -0.45%, compared to IMVT's ROE of -0.68%. Regarding short-term risk, RNAM is less volatile compared to IMVT. This indicates lower risk in terms of short-term price fluctuations for RNAM.Check IMVT's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
RNAM vs PCVX Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, PCVX has a market cap of 7.9B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while PCVX trades at $54.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas PCVX's P/E ratio is -7.94. In terms of profitability, RNAM's ROE is -0.45%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, RNAM is less volatile compared to PCVX. This indicates lower risk in terms of short-term price fluctuations for RNAM.Check PCVX's competition here
Metsera, Inc. (NASDAQ: MTSR)
RNAM vs MTSR Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas MTSR's P/E ratio is -23.58. In terms of profitability, RNAM's ROE is -0.45%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, RNAM is less volatile compared to MTSR. This indicates lower risk in terms of short-term price fluctuations for RNAM.Check MTSR's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
RNAM vs RYTM Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, RYTM has a market cap of 7.4B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while RYTM trades at $108.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas RYTM's P/E ratio is -34.53. In terms of profitability, RNAM's ROE is -0.45%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, RNAM is less volatile compared to RYTM. This indicates lower risk in terms of short-term price fluctuations for RNAM.Check RYTM's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
RNAM vs IBRX Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, IBRX has a market cap of 7.3B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while IBRX trades at $6.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas IBRX's P/E ratio is -8.20. In terms of profitability, RNAM's ROE is -0.45%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, RNAM is less volatile compared to IBRX. This indicates lower risk in terms of short-term price fluctuations for RNAM.Check IBRX's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
RNAM vs COGT Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, COGT has a market cap of 6.9B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while COGT trades at $40.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas COGT's P/E ratio is -19.27. In terms of profitability, RNAM's ROE is -0.45%, compared to COGT's ROE of -0.83%. Regarding short-term risk, RNAM is less volatile compared to COGT. This indicates lower risk in terms of short-term price fluctuations for RNAM.Check COGT's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
RNAM vs MIRM Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, MIRM has a market cap of 6.8B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while MIRM trades at $112.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas MIRM's P/E ratio is -8.25. In terms of profitability, RNAM's ROE is -0.45%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, RNAM is less volatile compared to MIRM. This indicates lower risk in terms of short-term price fluctuations for RNAM.Check MIRM's competition here
Merus N.V. (NASDAQ: MRUS)
RNAM vs MRUS Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas MRUS's P/E ratio is -17.05. In terms of profitability, RNAM's ROE is -0.45%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, RNAM is similarly volatile compared to MRUS. This indicates similar risk in terms of short-term price fluctuations for RNAM.Check MRUS's competition here
Arcellx, Inc. (NASDAQ: ACLX)
RNAM vs ACLX Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas ACLX's P/E ratio is -28.27. In terms of profitability, RNAM's ROE is -0.45%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, RNAM is less volatile compared to ACLX. This indicates lower risk in terms of short-term price fluctuations for RNAM.Check ACLX's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
RNAM vs RETA Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas RETA's P/E ratio is -66.29. In terms of profitability, RNAM's ROE is -0.45%, compared to RETA's ROE of +0.47%. Regarding short-term risk, RNAM is less volatile compared to RETA. This indicates lower risk in terms of short-term price fluctuations for RNAM.Check RETA's competition here
CG Oncology Inc. (NASDAQ: CGON)
RNAM vs CGON Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, CGON has a market cap of 6.4B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while CGON trades at $72.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas CGON's P/E ratio is -31.17. In terms of profitability, RNAM's ROE is -0.45%, compared to CGON's ROE of -0.23%. Regarding short-term risk, RNAM is less volatile compared to CGON. This indicates lower risk in terms of short-term price fluctuations for RNAM.Check CGON's competition here
Erasca, Inc. (NASDAQ: ERAS)
RNAM vs ERAS Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, ERAS has a market cap of 6.3B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while ERAS trades at $18.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas ERAS's P/E ratio is -19.53. In terms of profitability, RNAM's ROE is -0.45%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, RNAM is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for RNAM.Check ERAS's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
RNAM vs XENE Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, XENE has a market cap of 6.3B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while XENE trades at $64.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas XENE's P/E ratio is -13.82. In terms of profitability, RNAM's ROE is -0.45%, compared to XENE's ROE of -0.49%. Regarding short-term risk, RNAM is less volatile compared to XENE. This indicates lower risk in terms of short-term price fluctuations for RNAM.Check XENE's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
RNAM vs CNTA Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas CNTA's P/E ratio is -22.63. In terms of profitability, RNAM's ROE is -0.45%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, RNAM is similarly volatile compared to CNTA. This indicates similar risk in terms of short-term price fluctuations for RNAM.Check CNTA's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
RNAM vs PTCT Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, PTCT has a market cap of 6.3B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while PTCT trades at $75.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas PTCT's P/E ratio is -32.36. In terms of profitability, RNAM's ROE is -0.45%, compared to PTCT's ROE of +1.00%. Regarding short-term risk, RNAM is less volatile compared to PTCT. This indicates lower risk in terms of short-term price fluctuations for RNAM.Check PTCT's competition here
Belite Bio, Inc (NASDAQ: BLTE)
RNAM vs BLTE Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, BLTE has a market cap of 6.3B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while BLTE trades at $155.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas BLTE's P/E ratio is -83.40. In terms of profitability, RNAM's ROE is -0.45%, compared to BLTE's ROE of -0.18%. Regarding short-term risk, RNAM is less volatile compared to BLTE. This indicates lower risk in terms of short-term price fluctuations for RNAM.Check BLTE's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
RNAM vs LGND Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, LGND has a market cap of 5.9B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while LGND trades at $296.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas LGND's P/E ratio is 35.53. In terms of profitability, RNAM's ROE is -0.45%, compared to LGND's ROE of +0.16%. Regarding short-term risk, RNAM is less volatile compared to LGND. This indicates lower risk in terms of short-term price fluctuations for RNAM.Check LGND's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
RNAM vs SRRK Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, SRRK has a market cap of 5.9B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while SRRK trades at $49.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas SRRK's P/E ratio is -13.75. In terms of profitability, RNAM's ROE is -0.45%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, RNAM is less volatile compared to SRRK. This indicates lower risk in terms of short-term price fluctuations for RNAM.Check SRRK's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
RNAM vs CDTX Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas CDTX's P/E ratio is -19.77. In terms of profitability, RNAM's ROE is -0.45%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, RNAM is similarly volatile compared to CDTX. This indicates similar risk in terms of short-term price fluctuations for RNAM.Check CDTX's competition here
Abcam plc (NASDAQ: ABCM)
RNAM vs ABCM Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, RNAM's ROE is -0.45%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, RNAM is less volatile compared to ABCM. This indicates lower risk in terms of short-term price fluctuations for RNAM.Check ABCM's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
RNAM vs ISEE Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas ISEE's P/E ratio is -22.44. In terms of profitability, RNAM's ROE is -0.45%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, RNAM is less volatile compared to ISEE. This indicates lower risk in terms of short-term price fluctuations for RNAM.Check ISEE's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
RNAM vs APLS Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas APLS's P/E ratio is 38.35. In terms of profitability, RNAM's ROE is -0.45%, compared to APLS's ROE of +0.40%. Regarding short-term risk, RNAM is less volatile compared to APLS. This indicates lower risk in terms of short-term price fluctuations for RNAM.Check APLS's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
RNAM vs TVTX Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, TVTX has a market cap of 5.2B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while TVTX trades at $55.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas TVTX's P/E ratio is -254.14. In terms of profitability, RNAM's ROE is -0.45%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, RNAM is less volatile compared to TVTX. This indicates lower risk in terms of short-term price fluctuations for RNAM.Check TVTX's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
RNAM vs TERN Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas TERN's P/E ratio is -51.41. In terms of profitability, RNAM's ROE is -0.45%, compared to TERN's ROE of -0.20%. Regarding short-term risk, RNAM is less volatile compared to TERN. This indicates lower risk in terms of short-term price fluctuations for RNAM.Check TERN's competition here
Veradermics, Incorporated (NYSE: MANE)
RNAM vs MANE Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, MANE has a market cap of 4.7B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while MANE trades at $111.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas MANE's P/E ratio is -35.45. In terms of profitability, RNAM's ROE is -0.45%, compared to MANE's ROE of -0.84%. Regarding short-term risk, RNAM is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for RNAM.Check MANE's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
RNAM vs CRSP Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, CRSP has a market cap of 4.6B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while CRSP trades at $47.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas CRSP's P/E ratio is -9.31. In terms of profitability, RNAM's ROE is -0.45%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, RNAM is less volatile compared to CRSP. This indicates lower risk in terms of short-term price fluctuations for RNAM.Check CRSP's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
RNAM vs DFTX Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, DFTX has a market cap of 4.6B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while DFTX trades at $41.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas DFTX's P/E ratio is N/A. In terms of profitability, RNAM's ROE is -0.45%, compared to DFTX's ROE of -1.02%. Regarding short-term risk, RNAM is less volatile compared to DFTX. This indicates lower risk in terms of short-term price fluctuations for RNAM.Check DFTX's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
RNAM vs FOLD Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas FOLD's P/E ratio is -161.00. In terms of profitability, RNAM's ROE is -0.45%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, RNAM is similarly volatile compared to FOLD. This indicates similar risk in terms of short-term price fluctuations for RNAM.Check FOLD's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
RNAM vs AKRO Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas AKRO's P/E ratio is -14.57. In terms of profitability, RNAM's ROE is -0.45%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, RNAM is less volatile compared to AKRO. This indicates lower risk in terms of short-term price fluctuations for RNAM.Check AKRO's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
RNAM vs ALPN Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas ALPN's P/E ratio is -101.52. In terms of profitability, RNAM's ROE is -0.45%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, RNAM is less volatile compared to ALPN. This indicates lower risk in terms of short-term price fluctuations for RNAM.Check ALPN's competition here
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD)
RNAM vs ACAD Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, ACAD has a market cap of 4.5B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while ACAD trades at $26.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas ACAD's P/E ratio is 12.75. In terms of profitability, RNAM's ROE is -0.45%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, RNAM is less volatile compared to ACAD. This indicates lower risk in terms of short-term price fluctuations for RNAM.Check ACAD's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
RNAM vs CAI Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, CAI has a market cap of 4.4B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while CAI trades at $15.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas CAI's P/E ratio is -85.75. In terms of profitability, RNAM's ROE is -0.45%, compared to CAI's ROE of +0.06%. Regarding short-term risk, RNAM is less volatile compared to CAI. This indicates lower risk in terms of short-term price fluctuations for RNAM.Check CAI's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
RNAM vs EWTX Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, EWTX has a market cap of 4.3B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while EWTX trades at $40.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas EWTX's P/E ratio is -24.31. In terms of profitability, RNAM's ROE is -0.45%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, RNAM is less volatile compared to EWTX. This indicates lower risk in terms of short-term price fluctuations for RNAM.Check EWTX's competition here
Dyne Therapeutics, Inc. (NASDAQ: DYN)
RNAM vs DYN Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, DYN has a market cap of 4.3B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while DYN trades at $25.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas DYN's P/E ratio is -8.04. In terms of profitability, RNAM's ROE is -0.45%, compared to DYN's ROE of -0.58%. Regarding short-term risk, RNAM is less volatile compared to DYN. This indicates lower risk in terms of short-term price fluctuations for RNAM.Check DYN's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
RNAM vs DNTH Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, DNTH has a market cap of 4.2B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while DNTH trades at $101.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas DNTH's P/E ratio is -24.60. In terms of profitability, RNAM's ROE is -0.45%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, RNAM is less volatile compared to DNTH. This indicates lower risk in terms of short-term price fluctuations for RNAM.Check DNTH's competition here
Opthea Limited (NASDAQ: OPT)
RNAM vs OPT Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas OPT's P/E ratio is -1.52. In terms of profitability, RNAM's ROE is -0.45%, compared to OPT's ROE of +1.18%. Regarding short-term risk, RNAM is similarly volatile compared to OPT. This indicates similar risk in terms of short-term price fluctuations for RNAM.Check OPT's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
RNAM vs MRTX Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas MRTX's P/E ratio is -4.82. In terms of profitability, RNAM's ROE is -0.45%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, RNAM is less volatile compared to MRTX. This indicates lower risk in terms of short-term price fluctuations for RNAM.Check MRTX's competition here
Celcuity Inc. (NASDAQ: CELC)
RNAM vs CELC Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, CELC has a market cap of 4B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while CELC trades at $82.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas CELC's P/E ratio is -21.14. In terms of profitability, RNAM's ROE is -0.45%, compared to CELC's ROE of -2.45%. Regarding short-term risk, RNAM is less volatile compared to CELC. This indicates lower risk in terms of short-term price fluctuations for RNAM.Check CELC's competition here
Viking Therapeutics, Inc. (NASDAQ: VKTX)
RNAM vs VKTX Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, VKTX has a market cap of 3.9B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while VKTX trades at $33.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas VKTX's P/E ratio is -8.18. In terms of profitability, RNAM's ROE is -0.45%, compared to VKTX's ROE of -0.71%. Regarding short-term risk, RNAM is less volatile compared to VKTX. This indicates lower risk in terms of short-term price fluctuations for RNAM.Check VKTX's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
RNAM vs CPRX Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas CPRX's P/E ratio is 12.30. In terms of profitability, RNAM's ROE is -0.45%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, RNAM is similarly volatile compared to CPRX. This indicates similar risk in terms of short-term price fluctuations for RNAM.Check CPRX's competition here
Enliven Therapeutics, Inc. (NASDAQ: ELVN)
RNAM vs ELVN Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, ELVN has a market cap of 3.8B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while ELVN trades at $53.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas ELVN's P/E ratio is -32.19. In terms of profitability, RNAM's ROE is -0.45%, compared to ELVN's ROE of -0.21%. Regarding short-term risk, RNAM is less volatile compared to ELVN. This indicates lower risk in terms of short-term price fluctuations for RNAM.Check ELVN's competition here
Denali Therapeutics Inc. (NASDAQ: DNLI)
RNAM vs DNLI Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, DNLI has a market cap of 3.8B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while DNLI trades at $24.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas DNLI's P/E ratio is -8.35. In terms of profitability, RNAM's ROE is -0.45%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, RNAM is less volatile compared to DNLI. This indicates lower risk in terms of short-term price fluctuations for RNAM.Check DNLI's competition here
RayzeBio, Inc. Common Stock (NASDAQ: RYZB)
RNAM vs RYZB Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas RYZB's P/E ratio is -57.86. In terms of profitability, RNAM's ROE is -0.45%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, RNAM is less volatile compared to RYZB. This indicates lower risk in terms of short-term price fluctuations for RNAM.Check RYZB's competition here
CymaBay Therapeutics, Inc. (NASDAQ: CBAY)
RNAM vs CBAY Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas CBAY's P/E ratio is -32.81. In terms of profitability, RNAM's ROE is -0.45%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, RNAM is less volatile compared to CBAY. This indicates lower risk in terms of short-term price fluctuations for RNAM.Check CBAY's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
RNAM vs ADPT Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, ADPT has a market cap of 3.6B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while ADPT trades at $22.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas ADPT's P/E ratio is -41.70. In terms of profitability, RNAM's ROE is -0.45%, compared to ADPT's ROE of -0.24%. Regarding short-term risk, RNAM is less volatile compared to ADPT. This indicates lower risk in terms of short-term price fluctuations for RNAM.Check ADPT's competition here
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT)
RNAM vs ARQT Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, ARQT has a market cap of 3.6B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while ARQT trades at $28.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas ARQT's P/E ratio is -947.33. In terms of profitability, RNAM's ROE is -0.45%, compared to ARQT's ROE of -0.01%. Regarding short-term risk, RNAM is less volatile compared to ARQT. This indicates lower risk in terms of short-term price fluctuations for RNAM.Check ARQT's competition here
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX)
RNAM vs SWTX Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas SWTX's P/E ratio is -13.78. In terms of profitability, RNAM's ROE is -0.45%, compared to SWTX's ROE of -0.47%. Regarding short-term risk, RNAM is similarly volatile compared to SWTX. This indicates similar risk in terms of short-term price fluctuations for RNAM.Check SWTX's competition here
Legend Biotech Corporation (NASDAQ: LEGN)
RNAM vs LEGN Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, LEGN has a market cap of 3.5B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while LEGN trades at $19.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas LEGN's P/E ratio is -28.00. In terms of profitability, RNAM's ROE is -0.45%, compared to LEGN's ROE of -0.25%. Regarding short-term risk, RNAM is less volatile compared to LEGN. This indicates lower risk in terms of short-term price fluctuations for RNAM.Check LEGN's competition here
Telix Pharmaceuticals Limited (NASDAQ: TLX)
RNAM vs TLX Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, TLX has a market cap of 3.5B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while TLX trades at $10.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas TLX's P/E ratio is -553.80. In terms of profitability, RNAM's ROE is -0.45%, compared to TLX's ROE of -0.02%. Regarding short-term risk, RNAM is less volatile compared to TLX. This indicates lower risk in terms of short-term price fluctuations for RNAM.Check TLX's competition here
IDEAYA Biosciences, Inc. (NASDAQ: IDYA)
RNAM vs IDYA Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, IDYA has a market cap of 3.4B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while IDYA trades at $36.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas IDYA's P/E ratio is -22.60. In terms of profitability, RNAM's ROE is -0.45%, compared to IDYA's ROE of -0.14%. Regarding short-term risk, RNAM is less volatile compared to IDYA. This indicates lower risk in terms of short-term price fluctuations for RNAM.Check IDYA's competition here
Arcus Biosciences, Inc. (NYSE: RCUS)
RNAM vs RCUS Comparison July 2026
Avidity Biosciences Inc (NASDAQ: RNAM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RNAM stands at 11.3B. In comparison, RCUS has a market cap of 3.4B. Regarding current trading prices, RNAM is priced at $72.86 on the NASDAQ, while RCUS trades at $27.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RNAM currently has a P/E ratio of -17.39, whereas RCUS's P/E ratio is -8.32. In terms of profitability, RNAM's ROE is -0.45%, compared to RCUS's ROE of -0.69%. Regarding short-term risk, RNAM is less volatile compared to RCUS. This indicates lower risk in terms of short-term price fluctuations for RNAM.Check RCUS's competition here